No description available.

No description available.

Il est documenté que les enfants poursuivant une greffe de cellules souches hématopoïétiques présentent une altération du zinc plasmatique potentiellement défavorable à leur état clinique puisque ce minéral est impliqué dans l’hématopoïèse, la défense immunitaire, l’intégrité de la muqueuse digestive et la croissance. Ainsi, une carence en zinc pourrait affecter la reprise de l’hématopoïèse, la vulnérabilité aux infections, les diarrhées, les complications inflammatoires et la croissance de ces enfants. Actuellement, le zinc n’est pratiquement jamais dosé chez la clientèle pédiatrique du CHU Ste-Justine. Cette étude a documenté prospectivement le statut nutritionnel en zinc chez 21 sujets admis pour une GCSH dans ce centre. Sept différents moments ont été déterminés afin de suivre la tendance évolutive des taux plasmatiques de zinc et des paramètres d’intérêt (anthropométrie, biochimie et complications de la greffe) en fonction de la récupération fonctionnelle de la moelle osseuse. Au total, 43% des enfants ont présenté des taux de zinc plasmatique cliniquement associés à une carence (<9,9 μmol/L) à un moment ou l’autre de la période d’observation. Cependant, aucun moment n’a été identifié comme plus propice à cet avènement. L’altération du taux de zinc survient peu importe l’âge, le sexe, le type de greffe, le diagnostic ou la présence d’un soutien nutritionnel. Les apports habituels en zinc n’expliquent pas le statut déficient observé et l’usage d’une alimentation parentérale ne prévient pas l’occurrence de ce problème. Le statut nutritionnel précaire à l’admission pourrait servir à identifier les patients à risque d’une altération du statut en zinc car ceux-ci ont montré un plus faible poids pour l’âge (<25e percentile). De plus, des corrélations positives entre la préalbumine et les taux plasmatiques de zinc ont été identifiées. Cliniquement, un statut altéré en ce minéral a occasionné de plus longs et importants épisodes de diarrhées, une mucosite et une neutropénie prolongée, mais ces données ne diffèrent pas significativement de celles recueillies auprès de patients ayant présenté un statut normal en zinc. Cette étude permettra d’accorder une importance particulière à la surveillance du statut en zinc lors de la GCSH étant donné l’altération transitoire observée chez plusieurs individus et l’apparente augmentation des complications post-greffe associées à un tel état. Puisque l’influence des apports habituels en zinc ne suffit pas pour expliquer ce phénomène, davantage d’études sont nécessaires. / It has been previously documented that plasma zinc levels are lower in children who underwent a hematopoietic stem cell transplant (HSCT). Given the role of zinc in hematopoiesis, immune defense, intestinal integrity and growth, it is likely that zinc deficiency may negatively affect patient outcomes by influencing hematopoiesis recovery, vulnerability to infections, occurrence of diarrhea, inflammatory complications and growth. To date, monitoring of this trace element is not routinely done in children undergoing HSCT at Ste-Justine Hospital. In this prospective study, we assessed plasma zinc levels and zinc intakes in 21 children at seven different time points before and after HSCT. In addition, anthropometric and biochemistry parameters as well as complications were collected at the same time points. Our results showed a prevalence of zinc deficiency (<9.9 μmol/L) of 43%, however no specific time was associated with the occurrence of this deficiency. Gender, age, graft type, primary diagnosis and the use of a nutritional support did not significantly affect the prevalence of this deficiency state. Usual zinc intakes could not explain this impairment while the use of parenteral nutrition did not prevent its occurrence. A poor nutritional status at admission, defined by a low weight-for-age (<25th percentile), could help identifying high-risk patients. This association is strengthened by the positive correlation found between prealbumin and plasma zinc levels. Although an altered zinc status resulted in a longer duration of diarrhea and more stools per day as well as an extended period of mucositis and neutropenia, no significant difference was seen between patients with a normal and an impaired zinc status with regard to these outcomes. This study suggests the relevance of monitoring zinc nutritional status during HCST given the significant proportion of patients with impaired zinc status and the apparent increase in post-HCST complications seen in those patients. Since usual zinc intakes do not explain the alteration of zinc status of our study population, further studies are needed.

Immune cell niches are microenvironments that support the survival of specific hematopoietic cells. The size of a given niche is dependent on survival and proliferation signals provided. Modulation of niche size can be a useful therapeutic tool, and a better understanding of the factors that control the size of immune cell niches can lead to more targeted therapies. Here bone marrow and thymic niches were modulated with tyrosine kinase inhibition to achieve increased engraftment following stem cell transplantation (SCT). SCT resulting in mixed chimerism is curative for several benign blood diseases, but toxicities associated with myeloablative and cytotoxic conditioning regimens limit the application of SCT. Sunitinib inhibits multiple tyrosine kinases including KIT, an essential survival signal within the hematopoietic stem cell and thymic progenitor niches. Sunitinib therapy diminishes hematopoietic and thymic progenitor cells in mice and enhances accessibility of marrow and thymic niches to transplanted bone marrow. This provides a novel, non-cytotoxic approach to accomplish mixed hematopoietic chimerism. The observation that T cells undergo increased proliferation and accumulate in IL-7R deficient mice compared to other lymphopenic hosts raised questions about the factors that control the size of the T cell niche. Understanding these factors is useful in designing therapeutics to increase T cell responses for treatment of many diseases including cancer. Dendritic cells (DCs) are well known for their ability to modulate T cell responses; however, very little is known about the role of IL-7R signaling on DCs. The data presented here show that bone marrow derived DCs treated with IL-7 were less able to induce T cell proliferation in coculture. In vivo systems using CD11cDTR mice showed a role for IL-7 signaling on CD11c+ cells in T cell homeostasis. Together these data suggest that IL-7R signaling on DCs is important for regulating the size of the T cell niche.

Orientadores: Ester Maria Danielli Nicola, Eulália Sakano / Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-25T13:39:38Z (GMT). No. of bitstreams: 1 Ortiz_Erica_D.pdf: 2854168 bytes, checksum: c4f7e3d14049e592b11a3b339481fa12 (MD5) Previous issue date: 2014 / Resumo: Introdução: Acredita-se que a imunossupressão seja única causa para maior prevalência de rinossinusites (RS) no transplantado de células tronco hematopoiéticas (TCTH) principalmente naqueles com Doença do Enxerto contra o Hospedeiro (DECH) crônica. Pacientes submetidos ao TCTH podem apresentar alterações nasossinusais, que podem se relacionar ao próprio transplante, assim como pelo regime de condicionamento ou pela DECH. Entretanto, estas alterações nasossinusais não estão bem descritas na literatura assim como a associação entre estas e a rinossinusite. Objetivo: verificar a histologia e ultraestrutura da mucosa nasossinusal com RS no TCTH com e sem DECH; e verificar a influencia da RS nas possíveis alterações histológicas nestes pacientes. Método: estudo prospectivo exploratório de coorte transversal com análise estatística de dados obtidos da avaliação de mucosa de processo unciforme de pacientes transplantados com (16) e sem DECH (8) com RS; através da microscopia eletrônica de transmissão e óptica. Comparação da recorrência das RS e alterações histológicas. Resultados: 47% (14) tiveram apenas 1 ou 2 episódios e 33%, mais de 3 episódios de rinossinusite. Apenas a presença de microvilosidades foi significativamente maior nos pacientes sem GVHD (p=0,05). Não houve diferença significativa na quantidade de cílios, ultraestrutura ciliar, metaplasia escamosa, células caliciformes, vacuolização citoplasmática, densidade do infiltrado inflamatório, linfócitos, eosinófilos e corpúsculos apoptóticos intraepiteliais, glândulas mucosas, espessura da membrana basal, edema e fibrose subepiteliais entre os grupos com e sem DECH. Houve diminuição significante de cílios conforme maior recorrência de rinossinusite (p=0,008). Conclusão: pacientes com RS e TCTH não apresentaram diferenças nas alterações histológicas nasossinusais, exceto aumento de microvilosidades naqueles sem a DECH. Os transplantados com e sem DECH apresentaram somente diminuição dos cílios conforme o aumento da recorrência de RS / Abstract: INTRODUCTION: It is believed that immunosuppression is the sole cause for the occurrence of rhinosinusitis in hematopoietic stem cell transplant (HSCT). There is a high incidence of sinusitis in recipient patients, especially in those with Chronic Graft-Versus-Host disease (GVHD). Histopathological abnormalities were described in recipients¿ sinus mucosa compared to immunocompetent patients. There were also mucosal abnormalities related to cytotoxicity in the transplanted patients with chronic GVHD but no difference in ultrastructure between HSCT patients with and without GVHD, except for increased goblet cells in patients without GVHD. The relation between the sinonasal mucosa abnormalities of patients with and without GVHD and rhinosinusitis is not well established yet. OBJECTIVE: To verify the ultrastructure of the sinonasal mucosa of HSCT with and without GVHD with rhinosinusitis to understand the cause of high sinusitis incidence in recipients with and without GVHD. METHOD: A prospective study with preliminary exploratory statistical analysis of data obtained from the evaluation of the uncinate process mucosa of patients transplanted with (16) and without GVHD (8) with rhinosinusitis by transmission electron and optical microscopy. RESULTS: Of the patients, 47% (14) had only 1 or 2 episodes, and 33% had more than 3 episodes of rhinosinusitis. Only the presence of microvilli was significantly higher in patients without GVHD. There was no significant difference in the amount of cilia, ciliary ultrastructure, squamous metaplasia, goblet cells, vacuolization, density of the inflammatory infiltrate, intraepithelial lymphocytes, eosinophils, mucous glands, apoptotic corpuscles intraepithelial basement membrane thickness, edema and subepithelial fibrosis between groups. There was a significant decrease of cilia with higher recurrence of rhinosinusitis. CONCLUSION: There was an increase in microvilli HSCT without GVHD with rhinosinusitis, and the ultrastructure and histological changes of HSCT with and without GVHD did not change with the recurrence of rhinosinusitis. However, there was a decrease of cilia in the epithelium of the sinonasal HSCT with higher recurrence of rhinosinusitis / Doutorado / Otorrinolaringologia / Doutora em Ciências Médicas

Introduction L’allogreffe de cellules souches hématopoïétiques est un traitement avec un potentiel curatif chez une minorité de patients ayant un diagnostic myélome multiple. Malheureusement, ce traitement est associé à un taux élevé de complications, incluant une probabilité élevée de rechute et/ou de GVH chronique limitant. L’objectif principal de cette étude est de déterminer si un entretien au bortezomib (BTZ) post-allogreffe permet de diminuer l’incidence et la sévérité de la maladie du greffon contre l’hôte (GVH) chronique. Les objectifs secondaires étaient d’évaluer la prise d’immunosuppresseur, de déterminer l’atteinte d’organe et la survie (OS et PFS) chez les patients ayant reçu ou pas du BTZ en entretien. Méthodes Dans cette étude rétrospective, nous avons comparé 46 patients ayant reçu du BTZ en entretien post-allogreffe à 61 patients n’ayant pas reçu d’entretien. Nous avons étudié l’impact du BTZ sur l’incidence et la sévérité de la GVH chronique en utilisant les critères du NIH de 2014. Résultats À 2 ans, l’incidence globale (61.2% vs 83.6%, p=0.001) et modérée/sévère (44.5% vs 77.0%, p=0.001) de GVH chronique était significativement inférieure chez les patients ayant reçu du BTZ en entretien. Les atteintes buccale (43% vs 67%, p=0.018) et ophtalmique (9% vs 41%, p=0.001) étaient diminuées de manière significative lors du diagnostic initial de la GVH chronique chez ces patients ayant reçu un entretien post-allogreffe. Une diminution de l’usage des immunosuppresseurs, dont les corticostéroïdes systémiques (45.1% vs 76.4%, p<0.001), du mycophenolate mofetil (15.5% vs 28.2%, p=0.031) et du tacrolimus (34.5% vs 70.6%, p<0.001) a été observée chez les patients ayant reçu le BTZ. La probabilité d’être vivant et sans immunosuppresseur à 3 ans post-allogreffe était de 77% chez les patients de la cohorte BTZ et 56% dans la cohorte contrôle (p=0.046). Conclusion En conclusion, un entretien avec du BTZ post-allogreffe permet de diminuer l’incidence et la sévérité de la GVH chronique. Ceci devrait donc être considéré comme une option valide chez les patients avec un myélome multiple traités avec une allogreffe. / Background Allogeneic hematopoietic cell transplant (HCT) has curative potential in myeloma but remains hampered by high rates of relapse and chronic GVHD. The primary endpoint of this study was to determine if BTZ maintenance decreases the incidence and severity of chronic GVHD using NIH criteria. The secondary endpoints were to determine the immunosuppression burden, organ involvement and survival (OS, PFS) in patients receiving or not BTZ. Study Design In this retrospective study, we compared the outcome of 46 myeloma patients who received BTZ after upfront tandem auto-allo HCT to 61 patients without maintenance. We explored the impact of bortezomib (BTZ) maintenance on incidence and severity of chronic GVHD using the 2014 NIH criteria. Results At 2 years, incidences of overall (61.2% vs 83.6%, p=0.001) and moderate/severe chronic GVHD (44.5% vs 77.0%, p=0.001) were significantly lower in BTZ recipients who had less mouth (43% vs 67%, p=0.018) and eyes (9% vs 41%, p=0.001) involvement at initial diagnosis. We report a lower use of systemic steroids (45.1% vs 76.4%, p<0.001), mycophenolate mofetil (15.5% vs 28.2%, p=0.031) and tacrolimus (34.5% vs 70.6%, p<0.001) in BTZ recipients. Probability of being alive and off systemic immunosuppressants at 3 years was 77% in BTZ recipients and 56% in controls (p=0.046). Conclusion In summary, BTZ maintenance improved incidence and severity of chronic GVHD and should be considered as a valid option in myeloma patients receiving upfront tandem auto-allo HCT.

A esclerose múltipla (EM) é uma doença desmielinizante inflamatória crônica recorrente, restrita ao sistema nervoso central (SNC), cuja característica histológica é a ocorrência de desmielinização relacionada com infiltrado inflamatório perivenular com relativa preservação axonal. A forma clássica da doença se caracteriza pela recorrência de ataques (surtos), seguidos de remissão dos sintomas (RRMS), com a presença de múltiplas lesões focais dispersas pelo SNC (dissociação espacial) com processo inflamatório exuberante na fase aguda, coexistindo com lesões crônicas (dissociação temporal) sem atividade inflamatória evidenciavel pela quebra de barreira hematoencefálica e realce na fase contrastada na imagem de ressonância magnética (MRI). Alguns pacientes tem uma evolução benigna, permanecendo livre de sequelas significativas por mais de 20 anos da doença. Outros pacientes têm uma forma agressiva da doença, ficando restritos à cadeira de rodas em 8 a 10 anos de evolução. Um desafio é modificar o curso desta forma agressiva, o que pode ser feito com o uso de imunomoduladores, quimioterápicos e, eventualmente, transplante autólogo de células tronco hematopoiéticas (aHSCT). O objetivo da utilização do aHSCT é a restauração da atividade imunológica livre dos ataques à mielina (\"autoimune reset\"). Uma das maneiras de se monitorar a eficácia do tratamento é a identificação da ocorrência de novas lesões e de lesões com reforço visíveis em exames de RM seriados. Objetivo: Testar a hipótese de que o tratamento de pacientes com EM, utilizando AHSCT, foi eficaz em evitar a recorrência de inflamação e o aparecimento de novas lesões visíveis na SB ao exame de MRI, a longo prazo. Resultados: Na nossa Instituição, cerca de 66 pacientes portadores de EM foram tratados com aHSCT no período de 2004 a 2011, sendo seguidos desde então pelas disciplinas de hematologia, neurologia/neuroimunologia e pela seção de RM do CCIFM-HCRP. Método: Foram revisados os exames de RM de encéfalo adquiridos de maneira prospectiva e protocolada, de 76 pacientes submetidos ao aHSCT, com seguimento por MRI há mais de cinco anos. As imagens de RM foram arquivadas nos servidores do CCIFM, foram recuperadas, anonimizadas e revistas por pelo menos dois radiologistas experientes, de maneira independente e por confrontação. Foi considerada falha terapêutica a identificação de lesões novas e/ou lesões com reativação inflamatória. Resultados: Dez pacientes foram excluídos. Doze pacientes (18,18%) apresentaram novas lesões ou recorrência do processo inflamatório, com reforço. Conclusão: Na nossa amostra o aHSCT foi capaz de controlar a recorrência de lesões e da atividade inflamatória perceptível na RM em mais de 87% dos casos, caracterizando uma importante opção terapêutica de segunda linha nos casos de maior agressividade da doença / Multiple sclerosis (MS) is a recurrent chronic inflammatory demyelinating disease, restricted to the central nervous system (CNS), whose histological feature is the occurrence of perivenular inflammatory infiltrate, leading to demyelination with relative axonal preservation. The classic form of the disease is characterized by the recurrence of attacks (outbreaks), followed by remission of symptoms (RRMS), with the presence of multiple focal lesions dispersed by the CNS (spatial dissociation) with exuberant inflammatory process in the acute phase, coexisting with chronic lesions (Temporal dissociation) without inflammatory activity evidenced by the breakdown of blood-brain barrier and contrast-enhanced contrast-enhanced magnetic resonance imaging (MRI). Some patients have a benign course, remaining free of significant sequelae for more than 20 years of the disease. Other patients have an aggressive form of the disease, being restricted to the wheelchair in 8 to 10 years of evolution. One challenge is to modify the course in this aggressive way, which can be done with the use of immunomodulators, chemotherapeutics and, eventually, autologous hematopoietic stem cell transplantation (aHSCT). The goal of using aHSCT is to restore immune activity free of myelin attacks (\"autoimmune reset\"). One of the ways to monitor treatment efficacy is to identify the occurrence of new lesions and visible reinforcing lesions on serial MRI scans. Objective: To test the hypothesis that the treatment of patients with MS using AHSCT was effective in avoiding the recurrence of inflammation and the appearance of new visible lesions in SB at the long-term examination of MRI. Results: At our institution, approximately 66 patients with MS were treated with aHSCT from 2004 to 2011, followed by the hematology, neurology / neuroimmunology and MRI sections of the CCIFM-HCRP. Methods: Brain and MRI scans acquired in a prospective and protocolized way from 76 patients who underwent aHSCT were followed up with MRI for more than five years. The MR images were archived on the CCIFM servers, retrieved, anonymised and reviewed by at least two experienced radiologists, independently and by confrontation. The identification of new lesions and / or lesions with inflammatory reactivation was considered therapeutic failure. Results: Ten patients were excluded. Twelve patients (18.18%) presented new lesions or recurrence of the inflammatory process, with reinforcement. Conclusion: In our sample, aHSCT was able to control the recurrence of lesions and the inflammatory activity detected in MRI in more than 87% of the cases, characterizing an important second line therapeutic option in the cases of greater aggressiveness of the disease.

A esclerose múltipla (EM) é uma doença desmielinizante inflamatória crônica recorrente, restrita ao sistema nervoso central (SNC), cuja característica histológica é a ocorrência de desmielinização relacionada com infiltrado inflamatório perivenular com relativa preservação axonal. A forma clássica da doença se caracteriza pela recorrência de ataques (surtos), seguidos de remissão dos sintomas (RRMS), com a presença de múltiplas lesões focais dispersas pelo SNC (dissociação espacial) com processo inflamatório exuberante na fase aguda, coexistindo com lesões crônicas (dissociação temporal) sem atividade inflamatória evidenciavel pela quebra de barreira hematoencefálica e realce na fase contrastada na imagem de ressonância magnética (MRI). Alguns pacientes tem uma evolução benigna, permanecendo livre de sequelas significativas por mais de 20 anos da doença. Outros pacientes têm uma forma agressiva da doença, ficando restritos à cadeira de rodas em 8 a 10 anos de evolução. Um desafio é modificar o curso desta forma agressiva, o que pode ser feito com o uso de imunomoduladores, quimioterápicos e, eventualmente, transplante autólogo de células tronco hematopoiéticas (aHSCT). O objetivo da utilização do aHSCT é a restauração da atividade imunológica livre dos ataques à mielina (\"autoimune reset\"). Uma das maneiras de se monitorar a eficácia do tratamento é a identificação da ocorrência de novas lesões e de lesões com reforço visíveis em exames de RM seriados. Objetivo: Testar a hipótese de que o tratamento de pacientes com EM, utilizando AHSCT, foi eficaz em evitar a recorrência de inflamação e o aparecimento de novas lesões visíveis na SB ao exame de MRI, a longo prazo. Resultados: Na nossa Instituição, cerca de 66 pacientes portadores de EM foram tratados com aHSCT no período de 2004 a 2011, sendo seguidos desde então pelas disciplinas de hematologia, neurologia/neuroimunologia e pela seção de RM do CCIFM-HCRP. Método: Foram revisados os exames de RM de encéfalo adquiridos de maneira prospectiva e protocolada, de 76 pacientes submetidos ao aHSCT, com seguimento por MRI há mais de cinco anos. As imagens de RM foram arquivadas nos servidores do CCIFM, foram recuperadas, anonimizadas e revistas por pelo menos dois radiologistas experientes, de maneira independente e por confrontação. Foi considerada falha terapêutica a identificação de lesões novas e/ou lesões com reativação inflamatória. Resultados: Dez pacientes foram excluídos. Doze pacientes (18,18%) apresentaram novas lesões ou recorrência do processo inflamatório, com reforço. Conclusão: Na nossa amostra o aHSCT foi capaz de controlar a recorrência de lesões e da atividade inflamatória perceptível na RM em mais de 87% dos casos, caracterizando uma importante opção terapêutica de segunda linha nos casos de maior agressividade da doença / Multiple sclerosis (MS) is a recurrent chronic inflammatory demyelinating disease, restricted to the central nervous system (CNS), whose histological feature is the occurrence of perivenular inflammatory infiltrate, leading to demyelination with relative axonal preservation. The classic form of the disease is characterized by the recurrence of attacks (outbreaks), followed by remission of symptoms (RRMS), with the presence of multiple focal lesions dispersed by the CNS (spatial dissociation) with exuberant inflammatory process in the acute phase, coexisting with chronic lesions (Temporal dissociation) without inflammatory activity evidenced by the breakdown of blood-brain barrier and contrast-enhanced contrast-enhanced magnetic resonance imaging (MRI). Some patients have a benign course, remaining free of significant sequelae for more than 20 years of the disease. Other patients have an aggressive form of the disease, being restricted to the wheelchair in 8 to 10 years of evolution. One challenge is to modify the course in this aggressive way, which can be done with the use of immunomodulators, chemotherapeutics and, eventually, autologous hematopoietic stem cell transplantation (aHSCT). The goal of using aHSCT is to restore immune activity free of myelin attacks (\"autoimmune reset\"). One of the ways to monitor treatment efficacy is to identify the occurrence of new lesions and visible reinforcing lesions on serial MRI scans. Objective: To test the hypothesis that the treatment of patients with MS using AHSCT was effective in avoiding the recurrence of inflammation and the appearance of new visible lesions in SB at the long-term examination of MRI. Results: At our institution, approximately 66 patients with MS were treated with aHSCT from 2004 to 2011, followed by the hematology, neurology / neuroimmunology and MRI sections of the CCIFM-HCRP. Methods: Brain and MRI scans acquired in a prospective and protocolized way from 76 patients who underwent aHSCT were followed up with MRI for more than five years. The MR images were archived on the CCIFM servers, retrieved, anonymised and reviewed by at least two experienced radiologists, independently and by confrontation. The identification of new lesions and / or lesions with inflammatory reactivation was considered therapeutic failure. Results: Ten patients were excluded. Twelve patients (18.18%) presented new lesions or recurrence of the inflammatory process, with reinforcement. Conclusion: In our sample, aHSCT was able to control the recurrence of lesions and the inflammatory activity detected in MRI in more than 87% of the cases, characterizing an important second line therapeutic option in the cases of greater aggressiveness of the disease.

Les maladies hématologiques, telles que les leucémies et les lymphomes, sont parmi les cancers les plus fréquents chez les jeunes adultes. Bien que la greffe de cellules souches (GCS) permet de traiter ceux-ci, de nombreux effets secondaires peuvent découler de ce traitement. Il est ainsi souhaité que les jeunes adultes développent une expertise quant à l’autogestion de leurs symptômes. Pourtant, peu de connaissances existent quant à leurs expériences d’autogestion. Cette étude avait pour but de décrire les expériences d’apprentissage quant à l’autogestion de jeunes adultes (18-39 ans) ayant reçu une GCS allogénique. Une étude qualitative descriptive interprétative (Thorne, 2016) a été réalisée auprès de jeunes adultes ayant reçu une GCS (n=7, moyenne d’âge de 26 ans, moyenne de 14,71 mois post GCS). Les résultats suggèrent que l’apprentissage de l’autogestion suivant une GCS est un processus évolutif décliné en cinq niveaux possédant des caractéristiques distinctes. De plus, différents facteurs influencent, positivement ou négativement, l’apprentissage de l’autogestion. Les résultats indiquent notamment que les jeunes adultes développent une conscience de leurs sensations corporelles (intéroception) qui leur permettent d’adapter leurs stratégies d’autogestion et de favoriser un meilleur contrôle de leurs symptômes. Finalement, différentes recommandations sont émises pour favoriser le développement de l’autogestion de jeunes adultes ayant reçu une GCS, telles que l’élaboration d’interventions éducatives selon différents niveaux d’apprentissage ainsi que la mise en place d’activités favorisant leur capacité d’intéroception, comme le yoga. / Hematological diseases, such as leukemia and lymphoma, are among the most common forms of cancers that can affect young adults. Hematopoietic stem cell transplantation is a common intervention to treat blood-related cancers such as leukemia and lymphoma. However, an allogeneic stem cell transplant (ASCT) can provoke many acute and chronic symptoms. Young adult cancer survivors are expected to develop expertise to self-manage these symptoms. Yet little is known about their self-management experiences. The purpose of this study was to describe self-management learning experiences of young adults (18-39 years old) following ASCT. An interpretive qualitative descriptive design (Thorne, 2016) was conducted with seven young adults who had undergone an ASCT (n=7, mean 26 years old, mean 14,71 months post-ASCT). The results suggest that learning self-management expertise following ASCT is progressive and was described into a five-level process with distinct characteristics. Certain factors could positively or negatively affect the learning process and hence the development of this self-management expertise. In addition, our results indicate that young adults developed body awareness (interoceptive ability) related to their symptoms. This ability allows young adults to adapt their self-management strategies and promote better control of their symptoms. Finally, various recommendations were made to promote self-management in young adults who have undergone an ASCT, including educational interventions

No description available.